← Search & browse all drugs
SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION › Corticosteroids and antiinfectives in combination
dexamethasone and antiinfectives
S01CA01
Forms & Strengths
- Ophthalmic suspension: dexamethasone 0.1% + anti-infective (e.g., neomycin, polymyxin B, tobramycin)
- Ophthalmic ointment: dexamethasone 0.1% + anti-infective combinations
Adult Dosing
- Suspension: Instill 1 to 2 drops into the conjunctival sac(s) every 4 to 6 hours
- Severe cases: Instill 1 to 2 drops hourly, tapering as inflammation subsides
- Ointment: Apply a small amount (approx. 0.5 inch ribbon) into the conjunctival sac(s) up to 3 to 4 times daily
Pediatric Dosing
- Safety and efficacy in pediatric patients below the age of 2 years have not been established
- Children >= 2 years: Use adult dosing regimens with caution and limit duration
Indications
- Steroid-responsive inflammatory ocular conditions where a bacterial infection or risk of bacterial ocular infection exists
- Post-operative ocular inflammation following cataract or ocular surgery
Mechanism of Action
- Dexamethasone: Potent corticosteroid that suppresses the inflammatory response by inhibiting phospholipase A2, reducing edema, fibrin deposition, capillary dilation, and leukocyte migration
- Anti-infective component: Provides bactericidal or bacteriostatic activity against susceptible gram-positive and/or gram-negative ocular pathogens
Contraindications
- Most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella
- Mycobacterial infection of the eye
- Fungal diseases of ocular structures
- Hypersensitivity to any component of the formulation
Adverse Reactions
- Elevated intraocular pressure with potential development of glaucoma
- Posterior subcapsular cataract formation
- Delayed wound healing
- Secondary ocular infection (bacterial, fungal, or viral)
- Transient stinging or burning upon instillation
Drug Interactions
- CYP3A4 inhibitors (e.g., ritonavir, cobicistat): May increase systemic exposure and risk of systemic corticosteroid adverse effects with chronic use
- Other topical ophthalmic medications: Allow at least a 5-minute interval between multiple topical agents
Curated Content: Needs Vetting Before Put to Clinical Use